JP2021532101A5 - - Google Patents
Info
- Publication number
- JP2021532101A5 JP2021532101A5 JP2021502987A JP2021502987A JP2021532101A5 JP 2021532101 A5 JP2021532101 A5 JP 2021532101A5 JP 2021502987 A JP2021502987 A JP 2021502987A JP 2021502987 A JP2021502987 A JP 2021502987A JP 2021532101 A5 JP2021532101 A5 JP 2021532101A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- alkyl
- group
- cycloalkyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 | |
| US62/701,313 | 2018-07-20 | ||
| PCT/US2019/042711 WO2020018975A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532101A JP2021532101A (ja) | 2021-11-25 |
| JP2021532101A5 true JP2021532101A5 (enExample) | 2022-07-25 |
| JP7320595B2 JP7320595B2 (ja) | 2023-08-03 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502987A Active JP7320595B2 (ja) | 2018-07-20 | 2019-07-19 | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12234245B2 (enExample) |
| EP (1) | EP3823974A1 (enExample) |
| JP (1) | JP7320595B2 (enExample) |
| KR (1) | KR20210034596A (enExample) |
| CN (1) | CN112513048A (enExample) |
| AR (1) | AR115822A1 (enExample) |
| AU (1) | AU2019306658A1 (enExample) |
| BR (1) | BR112021001044A2 (enExample) |
| CA (1) | CA3105521A1 (enExample) |
| CL (1) | CL2021000153A1 (enExample) |
| CO (1) | CO2021001530A2 (enExample) |
| CR (1) | CR20210022A (enExample) |
| IL (1) | IL279256A (enExample) |
| MA (1) | MA53172A (enExample) |
| MX (1) | MX2021000780A (enExample) |
| PE (1) | PE20211811A1 (enExample) |
| PH (1) | PH12021500005A1 (enExample) |
| SG (1) | SG11202013062VA (enExample) |
| TW (1) | TWI825134B (enExample) |
| UA (1) | UA128558C2 (enExample) |
| WO (1) | WO2020018975A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| CN113015730A (zh) | 2018-11-13 | 2021-06-22 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113166081A (zh) | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| JP2022518260A (ja) * | 2019-01-23 | 2022-03-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| AU2020312800B2 (en) | 2019-07-17 | 2026-04-23 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms) |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3158123A1 (en) * | 2019-11-12 | 2021-05-20 | Yonggang Wei | Amide derivative and preparation method therefore and use thereof in medicine |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| CA3175729A1 (en) * | 2020-03-16 | 2021-09-23 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CA3174837A1 (en) | 2020-04-15 | 2021-10-21 | Daniel Oehlrich | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| EP4135842B1 (en) | 2020-04-15 | 2024-10-23 | JANSSEN Pharmaceutica NV | Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| KR20230016658A (ko) | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| KR20230152016A (ko) | 2021-03-04 | 2023-11-02 | 얀센 파마슈티카 엔브이 | Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체 |
| CA3208414A1 (en) | 2021-03-04 | 2022-09-09 | Daniel Oehlrich | 4-amino-6-oxo-pyridazine derivatives modulating nlrp3 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| TW202246230A (zh) * | 2021-05-10 | 2022-12-01 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| CN116917282B (zh) * | 2021-05-10 | 2026-08-11 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
| AR126474A1 (es) * | 2021-07-19 | 2023-10-11 | Genentech Inc | Compuestos de sulfonimidamida y uso de los mismos |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| JP2025502732A (ja) | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| US20250388568A1 (en) * | 2022-07-06 | 2025-12-25 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| WO2024023266A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| CN119907797A (zh) | 2022-09-23 | 2025-04-29 | 默沙东有限责任公司 | 用作nod样受体蛋白3抑制剂的酞嗪衍生物 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025101716A1 (en) * | 2023-11-07 | 2025-05-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of trifunctionalized sulfur(vi) compounds |
| US20250223290A1 (en) | 2023-12-14 | 2025-07-10 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| TW202535370A (zh) | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| CN122555708A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| CN122555707A (zh) | 2024-01-17 | 2026-08-11 | Ac免疫有限公司 | 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物 |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2025222076A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases |
| CN119100956B (zh) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705555A (en) * | 1984-08-08 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Herbicidal triazines |
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DK1270565T3 (da) | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| BR0014003A (pt) | 1999-09-14 | 2002-05-21 | Pfizer Prod Inc | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
| AU2002341321A1 (en) | 2001-11-30 | 2003-06-10 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| CA2789665C (en) | 2010-02-22 | 2020-06-16 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
| TW201311693A (zh) | 2011-09-02 | 2013-03-16 | Kyowa Hakko Kirin Co Ltd | 化學激活激素受體活性調節劑 |
| WO2014190015A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| BR112018016671A2 (pt) | 2016-02-16 | 2018-12-26 | The University Of Queensland | sulfonilureias e compostos relacionados e uso do mesmo |
| MA44729A (fr) | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| CN110914256A (zh) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| TW201910314A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| AU2018317800A1 (en) | 2017-08-15 | 2020-02-13 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US11623922B2 (en) | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| JP2021529187A (ja) | 2018-07-03 | 2021-10-28 | ノバルティス アーゲー | Ｎｌｒｐモジュレータ |
| JP2021529780A (ja) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| AR117951A1 (es) | 2018-07-20 | 2021-09-08 | Gruenenthal Gmbh | Derivados de triazolquinoxalina adicionalmente sustituidos |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| MX2021000660A (es) | 2018-07-20 | 2021-03-25 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1. |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| CR20210235A (es) | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113166081A (zh) | 2018-11-13 | 2021-07-23 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| CN113286784A (zh) | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| JP2022518260A (ja) | 2019-01-23 | 2022-03-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物 |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| BR112022014480A2 (pt) | 2020-01-22 | 2022-09-13 | Hoffmann La Roche | Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| IL295120A (en) | 2020-01-29 | 2022-09-01 | Univ Illes Balears | alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers |
| US20230203064A1 (en) | 2020-04-23 | 2023-06-29 | Janssen Pharmaceutica Nv | Tricyclic compounds as inhibitors of nlrp3 |
| WO2021219784A1 (en) | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| KR20230016658A (ko) | 2020-05-28 | 2023-02-02 | 얀센 파마슈티카 엔.브이. | 화합물 |
| US12624010B2 (en) | 2020-06-19 | 2026-05-12 | Ac Immune Sa | Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of their use |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| KR20230152016A (ko) | 2021-03-04 | 2023-11-02 | 얀센 파마슈티카 엔브이 | Nlrp3을 조절하는 4-알콕시-6-옥소-피리다진 유도체 |
| CA3212725A1 (en) | 2021-04-29 | 2022-11-03 | Daniel Oehlrich | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282B (zh) | 2021-05-10 | 2026-08-11 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| WO2023275230A1 (en) | 2021-07-01 | 2023-01-05 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides |
-
2019
- 2019-07-19 MA MA053172A patent/MA53172A/fr unknown
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/pt unknown
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-19 UA UAA202100695A patent/UA128558C2/uk unknown
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/ko not_active Withdrawn
- 2019-07-19 CR CR20210022A patent/CR20210022A/es unknown
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en not_active Abandoned
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en not_active Ceased
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/zh active Pending
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/ja active Active
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/es unknown
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/es unknown
- 2019-07-22 TW TW108125886A patent/TWI825134B/zh not_active IP Right Cessation
- 2019-07-22 AR ARP190102055A patent/AR115822A1/es not_active Application Discontinuation
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US12234245B2/en active Active
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/es unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/es unknown
-
2024
- 2024-12-19 US US18/988,433 patent/US20250115618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530536A5 (enExample) | ||
| JP2020505381A5 (enExample) | ||
| JP2019131569A5 (enExample) | ||
| HRP20220362T1 (hr) | Biciklički kondenzirani heteroarilni ili arilni spojevi i njihova upotreba kao inhibitori irak4 | |
| JP2017523169A5 (enExample) | ||
| JP6640222B2 (ja) | ヘテロ環式誘導体およびその使用 | |
| JP2020502047A5 (enExample) | ||
| JP7843705B2 (ja) | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 | |
| JP2020519596A5 (enExample) | ||
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| JP2024523623A5 (enExample) | ||
| JP2022507506A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| HRP20200214T1 (hr) | Sulfoniluree i srodni spojevi i njihova uporaba | |
| JP2021502323A5 (enExample) | ||
| JP2021508318A5 (enExample) | ||
| EP2813509B1 (en) | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | |
| JP2005194283A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2007522142A5 (enExample) | ||
| JP2017537937A5 (enExample) | ||
| JP2016028076A5 (enExample) | ||
| JP2022506898A5 (enExample) | ||
| JP2017526731A5 (enExample) | ||
| JP2019531279A5 (enExample) |